Summary
Karyopharm announced an investor conference call following the June 2, 2026 ASCO oral presentation of full Phase 3 SENTRY trial results evaluating selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis.
What Happened
Karyopharm will host a conference call featuring senior management and Phase 3 SENTRY principal investigator Dr. John Mascarenhas following presentation of the complete dataset at ASCO 2026.
Previously reported topline results showed the study achieved statistically significant spleen volume reduction (SVR35), while secondary endpoints including hemoglobin stabilization and bone marrow fibrosis improvement did not demonstrate meaningful differences between treatment arms.
Deep Analysis
SENTRY is one of the most important myelofibrosis clinical events of 2026.
Selinexor introduces a differentiated mechanism through XPO1 inhibition, complementing JAK pathway blockade provided by ruxolitinib. Unlike next-generation JAK inhibitors, selinexor attempts to improve outcomes through restoration of tumor suppressor protein localization and broader modulation of malignant cell biology.
The mixed topline profile creates a challenging regulatory narrative. Spleen volume reduction remains an accepted clinical endpoint in myelofibrosis, but regulators, physicians, and payers increasingly focus on symptom improvement, anemia benefit, fibrosis modification, and overall durability.
The full ASCO dataset will determine whether selinexor can establish a meaningful commercial position in frontline myelofibrosis or remain a niche combination strategy.
The results are also strategically important for competitors developing next-generation therapies, including Lilly’s recently acquired Ajax Type II JAK2 inhibitor program.
Company / Product Background
Karyopharm Therapeutics is a biotechnology company focused on therapies targeting nuclear export biology.
Selinexor is an oral XPO1 inhibitor designed to block nuclear export of tumor suppressor proteins.
Ruxolitinib is the current JAK1/JAK2 inhibitor standard of care backbone in myelofibrosis.
Signal Extraction
– Major myelofibrosis catalyst event imminent
– XPO1 remains a differentiated therapeutic mechanism
– Regulatory pathway depends on totality of efficacy evidence
– Competitive implications for future MF drug development
Insilens Take
– Opportunity: First meaningful frontline combination beyond pure JAK inhibition
– Risk: Mixed efficacy profile may limit physician adoption
– Watch Signal: Symptom score, durability, anemia and fibrosis outcomes
– Action: Benchmark against emerging Type II JAK2 and disease-modifying programs
